SIRT1 and kidney disorder: Several drugs available in kidney disease have also been shown to be partially contribute to the activation of the sirt1, such as sodium glucose co-transporter two inhibitors (Packer, 2020), angiotensin-converting enzyme inhibitor (enalapril) (Veitch et al., 2021), angiotensin II receptor blocker (olmesartan) (Gu et al., 2016), and statins (Khayatan et al., 2022).